Characteristics of renal responders
| . | Renal responders (n = 20) . | Nonrenal responders (n = 28) . | P value . |
|---|---|---|---|
| Age, y | 62 (38-83) | 67 (40-80) | .16 |
| Baseline eGFR, mL/min/1.73 m2 | 54 (3-94) | 34 (6-100) | .1 |
| CKD 1-2 at diagnosis, n (%) | 10/20 (50%) | 3/28 (11%) | .003 |
| 24h-proteinuria at onset, g | 4.4 (0.9-12.8) | 2.5 (0.4-5.9) | .005 |
| M-spike g/L | 8 (2-38) | 11 (4-30) | .54 |
| Normal C3 level, n (%) | 11 (52%) | 19 (68%) | .33 |
| MGRS, n (%) | 9 (45%) | 20 (71%) | .12 |
| Specific chemotherapy, n (%) | 19 (95%) | 8 (29%) | .001 |
| Bortezomib -based regimen, n (%) | 17 (85%) | 5 (18%) | .0001 |
| Time from diagnosis to treatment, mo | 3.5 (1-19) | 14 (1-48) | .018 |
| Hematological response, n (%) | 15 (75%) | 2/26 (8%) | .0001 |
| . | Renal responders (n = 20) . | Nonrenal responders (n = 28) . | P value . |
|---|---|---|---|
| Age, y | 62 (38-83) | 67 (40-80) | .16 |
| Baseline eGFR, mL/min/1.73 m2 | 54 (3-94) | 34 (6-100) | .1 |
| CKD 1-2 at diagnosis, n (%) | 10/20 (50%) | 3/28 (11%) | .003 |
| 24h-proteinuria at onset, g | 4.4 (0.9-12.8) | 2.5 (0.4-5.9) | .005 |
| M-spike g/L | 8 (2-38) | 11 (4-30) | .54 |
| Normal C3 level, n (%) | 11 (52%) | 19 (68%) | .33 |
| MGRS, n (%) | 9 (45%) | 20 (71%) | .12 |
| Specific chemotherapy, n (%) | 19 (95%) | 8 (29%) | .001 |
| Bortezomib -based regimen, n (%) | 17 (85%) | 5 (18%) | .0001 |
| Time from diagnosis to treatment, mo | 3.5 (1-19) | 14 (1-48) | .018 |
| Hematological response, n (%) | 15 (75%) | 2/26 (8%) | .0001 |
M-spike, monoclonal spike.